

PRIOR AUTHORIZATION REQUEST FORM EOC ID: Rheumatoid arthritis (SAA)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
		Dhana
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	Ctata Lia ID:
Group Number:	NPI: Address:	State Lic ID:
Address:		
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following que	for this patient that may support a estions and sign.	pproval. Please answer the
Q1. What drug is being requested? *		
☐ Actemra (tocilizumab)- IV Formulation		
Actemra (tocilizumab) - SubQ Formulation		
☐ Cimzia (certolizumab)		
☐ Enbrel (etanercept)		
☐ Humira (adalimumab)		
☐ Kineret (anakinra)		
☐ Orencia (abatacept)- IV Formulation		
Orencia (abatacept) - SubQ Formulation		
Remicade (infliximab)		
Simponi (golimumab) - SubQ Formulation		
Q2. What diagnosis is this drug being prescribed for (pick of	one)? *	
☐ Rheumatoid arthritis ☐ Other		
Q3. Please provide ICD code(s) for diagnosis.		
Q4. Please indicate location of administration.		



PRIOR AUTHORIZATION REQUEST FORM **EOC ID:**

Rheumatoid arthritis (SAA)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:		
Patient Name:	Supervising Physician:		
☐ Home ☐ Long Term Care (LTC) facility			
☐ Physician office (drug from office stock)			
Physician office (drug from pharmacy with a prescription)			
Q5. Is the patient a NEW START to the requested medication?			
☐ Yes ☐ No			
Q6. Is the prescribing physician a Rheumatologist?			
☐ Yes ☐ No			
Q7. Has the patient previously failed methotrexate?			
☐ Yes ☐ No			
Q8. If the patient has NOT previously FAILED METHOTREXATE, does the patient have a contraindication to methotrexate?			
☐ Yes ☐ No			
Q9. If the patient has NOT previously FAILED METHOTREXATE, has the patient failed AT LEAST ONE OTHER DMARD (hydroxychloroquine, sulfasalazine, leflunomide))?			
Q10. If the patient has NOT previously FAILED METHOTREXATE, does the patient have a contraindication to OTHER DMARDs (hydroxychloroquine, sulfasalazine, leflunomide)?			
☐ Yes ☐ No			
Q11. If the request is for ACTEMRA, CIMZIA ORENCIA, SIMPONI, or KINERET, has the patient failed Enbrel and Humira?			
☐ Yes - Enbrel & Humira			
☐ No - Enbrel only			
☐ No - Humira Only			
☐ No - other (please specify)			
Patient has CONTRAINDICATION to Enbrel and Humi	ra		
Q12. Additional Comments			



error, please notify the sender immediately to arrange for the return of this document

PRIOR AUTHORIZATION REQUEST FORM EOC ID: Rheumatoid arthritis (SAA)

Phone: 800-728-7947 Fax back to: 866-880-4532

	the pharmacy drug benefit for your patient. Certain requests for coverage require review stions and fax this form to the number listed above. Please note any information left
	Prescriber Name:
Patient Name:	Supervising Physician:
Prescriber Signature	Date
	ing above, I certify that applying the standard review timeframe may or the enrollee's ability to regain maximum function
	dical necessity denial. Requesting providers may speak to the SWHP medical a opportunity to help impact the decision on a request before coverage has been
entity named above. The authorized recipient of this information is prohibit	the sender that is legally privileged. This information is intended only for the use of the individual or ited from disclosing this information to any other party. If you are not the intended recipient, you are reference to the contents of this document is strictly prohibited. If you have received this telecopy in